Metformin Reduces the Progression of Atherogenesis by Regulating the Sestrin2-mTOR Pathway in Obese and Diabetic Rats

Objective In previous research, we found that Sestrin2 has a strong association with plasma atherogenicity and combats the progression of atherogenesis by regulating the AMPK-mTOR pathway. Metformin, an activator of AMPK, is widely used as a first-line therapy for diabetes, but its role in preventi...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Saravanakumar Sundararajan, Isaivani Jayachandran, Gautam Kumar Pandey, Saravanakumar Venkatesan, Anusha Rajagopal, Kuppan Gokulakrishnan, Muthuswamy Balasubramanyam, Viswanathan Mohan, Nagaraj Manickam
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	The Korean Society of Lipid and Atherosclerosis 2023-09-01
Serie:	Journal of Lipid and Atherosclerosis
Soggetti:	metformin diabetes mellitus obesity atherosclerosis sestrin2
Accesso online:	https://www.e-jla.org/search.php?where=aview&id=10.12997/jla.2023.12.3.290&code=9992JLA&vmode=FULL
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!